VEGFA and ovarian cancer: Furthermore, migration of HUVECs, stimulated by ascitic fluid from patients with ovarian cancer (known to contain high levels of ET-1 and vascular endothelial growth factor (vEGF), was more effectively blocked by the ETB receptor antagonist, BQ-788 (55%) than the ETA receptor antagonist, BQ-123 (25%) [16].